Microscale screening of antibody libraries as maytansinoid antibody-drug conjugates

References

• Chari RV, Miller ML, Widdison WC. Antibody-drug conjugates: an emerging concept in cancer therapy. Angew Chem Int Ed Engl 2014; 53:3796-827; PMID:24677743; http://dx.doi.org/10.1002/anie.201307628
   PubMed Web of Science ®Google Scholar
• Sievers EL, Senter PD. Antibody-drug conjugates in cancer therapy. Annu Rev Med 2013; 64:15-29; PMID:23043493; http://dx.doi.org/10.1146/annurev-med-050311-201823
   PubMed Web of Science ®Google Scholar
• Teicher BA, Doroshow JH. The promise of antibody-drug conjugates. N Engl J Med 2012; 367:1847-8; PMID:23134386; http://dx.doi.org/10.1056/NEJMe1211736
   PubMed Web of Science ®Google Scholar
• Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh DY, Dieras V, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012; 367:1783-91; PMID:23020162; http://dx.doi.org/10.1056/NEJMoa1209124
   PubMed Web of Science ®Google Scholar
• Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Ramchandren R, Bartlett NL, Cheson BD, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012; 30:2183-9; PMID:22454421; http://dx.doi.org/10.1200/JCO.2011.38.0410
   PubMed Web of Science ®Google Scholar
• Chari RV. Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res 2008; 41:98-107; PMID:17705444; http://dx.doi.org/10.1021/ar700108g
   PubMed Web of Science ®Google Scholar
• Widdison WC, Wilhelm SD, Cavanagh EE, Whiteman KR, Leece BA, Kovtun Y, Goldmacher VS, Xie H, Steeves RM, et al. Semisynthetic maytansine analogues for the targeted treatment of cancer. J Med Chem 2006; 49:4392-408; PMID:16821799; http://dx.doi.org/10.1021/jm060319f
   PubMed Web of Science ®Google Scholar
• Singh R, Erickson HK. Antibody-cytotoxic agent conjugates: preparation and characterization. Methods Mol Biol 2009; 525:445-67, xiv; PMID:19252846; http://dx.doi.org/10.1007/978-1-59745-554-1_23
   PubMedGoogle Scholar
• Shih HH Discovery Process for Antibody-Based Therapeutics. In: Tabrizi MA, Bornstein GG, Klakamp SL, editors. Development of Antibody-Based Therapeutics. New York: Springer. 2012 pp. Nine-32.
   Google Scholar
• Polson AG, Williams M, Gray AM, Fuji RN, Poon KA, McBride J, Raab H, Januario T, Go M, et al. Anti-CD22-MCC-DM1: an antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin's lymphoma. Leukemia 2010; 24:1566-73; PMID:20596033; http://dx.doi.org/10.1038/leu.2010.141
   PubMed Web of Science ®Google Scholar
• Baselga J, Gelmon KA, Verma S, Wardley A, Conte P, Miles D, Bianchi G, Cortes J, McNally VA, et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 2010; 28:1138-44; PMID:20124182; http://dx.doi.org/10.1200/JCO.2009.24.2024
   PubMed Web of Science ®Google Scholar
• Ben-Kasus T, Schechter B, Lavi S, Yarden Y, Sela M. Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosis. Proc Natl Acad Sci U S A 2009; 106:3294-9; PMID:19218427; http://dx.doi.org/10.1073/pnas.0812059106
   PubMed Web of Science ®Google Scholar
• Koefoed K, Steinaa L, Soderberg JN, Kjaer I, Jacobsen HJ, Meijer PJ, Haurum JS, Jensen A, Kragh M, et al. Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor. MAbs 2011; 3:584-95; PMID:22123060; http://dx.doi.org/10.4161/mabs.3.6.17955
   PubMed Web of Science ®Google Scholar
• Owen SC, Patel N, Logie J, Pan G, Persson H, Moffat J, Sidhu SS, Shoichet MS. Targeting HER2+ breast cancer cells: Lysosomal accumulation of anti-HER2 antibodies is influenced by antibody binding site and conjugation to polymeric nanoparticles. J Control Release 2013; 172(2):395-404; PMID:23880472; http://dx.doi.org/10.1016/j.jconrel.2013.07.011
   PubMed Web of Science ®Google Scholar
• Zhou Y, Marks JD. Discovery of internalizing antibodies to tumor antigens from phage libraries. Methods Enzymol 2012; 502:43-66; PMID:22208981; http://dx.doi.org/10.1016/B978-0-12-416039-2.00003-3
   PubMed Web of Science ®Google Scholar
• Krebs B, Rauchenberger R, Reiffert S, Rothe C, Tesar M, Thomassen E, Cao M, Dreier T, Fischer D, et al. High-throughput generation and engineering of recombinant human antibodies. J Immunol Methods 2001; 254:67-84; PMID:11406154; http://dx.doi.org/10.1016/S0022-1759(01)00398-2
   PubMed Web of Science ®Google Scholar
• Stefano JE, Busch M, Hou L, Park A, Gianolio DA. Micro- and mid-scale maleimide-based conjugation of cytotoxic drugs to antibody hinge region thiols for tumor targeting. Methods Mol Biol 2013; 1045:145-71; PMID:23913146; http://dx.doi.org/10.1007/978-1-62703-541-5_9
   PubMedGoogle Scholar
• Kellner C, Bleeker WK, Lammerts van Bueren JJ, Staudinger M, Klausz K, Derer S, Glorius P, Muskulus A, de Goeij BE, et al. Human kappa light chain targeted Pseudomonas exotoxin A–identifying human antibodies and Fab fragments with favorable characteristics for antibody-drug conjugate development. J Immunol Methods 2011; 371:122-33; PMID:21756911; http://dx.doi.org/10.1016/j.jim.2011.06.023
   PubMed Web of Science ®Google Scholar
• Wakankar A, Chen Y, Gokarn Y, Jacobson FS. Analytical methods for physicochemical characterization of antibody drug conjugates. MAbs 2011; 3:161-72; PMID:21441786; http://dx.doi.org/10.4161/mabs.3.2.14960
   PubMed Web of Science ®Google Scholar
• Hermanson GT Bioconjugate Techniques, 2nd edition. London: Academic Press 2008.
   Google Scholar
• Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1:307-10; PMID:2868172; http://dx.doi.org/10.1016/S0140-6736(86)90837-8
   PubMed Web of Science ®Google Scholar
• Sun D, Whitty A, Papadatos J, Newman M, Donnelly J, Bowes S, Josiah S. Adopting a practical statistical approach for evaluating assay agreement in drug discovery. J Biomol Screen 2005; 10:508-16; PMID:16093560; http://dx.doi.org/10.1177/1087057105275725
   PubMed Web of Science ®Google Scholar
• Trneny M, Verhoef G, Dyer MJS, Yehuda DB, Patti C, Canales M, Lopez A, Awan F, Montgomery P, et al. Starlyte Phase II study of Coltuximab Ravtansine (CoR, SAR3419) Single Agent: Clinical Activity and Safety in Patients with Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL; NCT01472887). American Society for Clinical Oncology presentation. 2014. abstr. #8506.
   Google Scholar
• Lowe D, Dudgeon K, Rouet R, Schofield P, Jermutus L, Christ D. Aggregation, stability, and formulation of human antibody therapeutics. Adv Protein Chem Struct Biol 2011; 84:41-61; PMID:21846562; http://dx.doi.org/10.1016/B978-0-12-386483-3.00004-5
   PubMed Web of Science ®Google Scholar
• Lyon RP, Benjamin DR, Ryan MC Methods for Screening Antibodies. WO2011109308 A1. WIPO Patent Application. 2011 pp. PCT/US2011/026534.
   Google Scholar
• Lyon RP, Ryan MC, Kostner H, Meyer EB, Sutherland MS, Yu C, Gordon KA, Benjamin DR. Development of Parallel Conjugation and Assay Methodologies to Screen for Antibodies with Optimal Properties for use as Antibody-Drug Conjugates; 2010; Washington, DC abstr. #4394.
   Google Scholar
• Zimmerman ES, Heibeck TH, Gill A, Li X, Murray CJ, Madlansacay MR, Tran C, Uter NT, Yin G, et al. Production of site-specific antibody-drug conjugates using optimized non-natural amino acids in a cell-free expression system. Bioconjug Chem 2014; 25:351-61; PMID:24437342; http://dx.doi.org/10.1021/bc400490z
   PubMed Web of Science ®Google Scholar
• Michael S, Auld D, Klumpp C, Jadhav A, Zheng W, Thorne N, Austin CP, Inglese J, Simeonov A. A robotic platform for quantitative high-throughput screening. Assay Drug Dev Technol 2008; 6:637-57; PMID:19035846; http://dx.doi.org/10.1089/adt.2008.150
   PubMed Web of Science ®Google Scholar
• Stephanopoulos N, Francis MB. Choosing an effective protein bioconjugation strategy. Nat Chem Biol 2011; 7:876-84; PMID:22086289; http://dx.doi.org/10.1038/nchembio.720
   PubMed Web of Science ®Google Scholar
• Spicer CD, Davis BG. Selective chemical protein modification. Nat Commun 2014; 5:4740; PMID:25190082; http://dx.doi.org/10.1038/ncomms5740
   PubMed Web of Science ®Google Scholar
• McGinty RK, Kim J, Chatterjee C, Roeder RG, Muir TW. Chemically ubiquitylated histone H2B stimulates hDot1L-mediated intranucleosomal methylation. Nature 2008; 453:812-6; PMID:18449190; http://dx.doi.org/10.1038/nature06906
   PubMed Web of Science ®Google Scholar
• Popp MW, Dougan SK, Chuang TY, Spooner E, Ploegh HL. Sortase-catalyzed transformations that improve the properties of cytokines. Proc Natl Acad Sci U S A 2011; 108:3169-74; PMID:21297034; http://dx.doi.org/10.1073/pnas.1016863108
   PubMed Web of Science ®Google Scholar
• Li X, Fang T, Boons GJ. Preparation of well-defined antibody-drug conjugates through glycan remodeling and strain-promoted azide-alkyne cycloadditions. Angew Chem Int Ed Engl 2014; 53:7179-82; PMID:24862406; http://dx.doi.org/10.1002/anie.201402606
   PubMed Web of Science ®Google Scholar
• Drake PM, Albers AE, Baker J, Banas S, Barfield RM, Bhat AS, de Hart GW, Garofalo AW, Holder P, et al. Aldehyde tag coupled with HIPS chemistry enables the production of ADCs conjugated site-specifically to different antibody regions with distinct in vivo efficacy and PK outcomes. Bioconjug Chem 2014; 25:1331-41; PMID:24924618; http://dx.doi.org/10.1021/bc500189z
   PubMed Web of Science ®Google Scholar
• Jost C, Pluckthun A. Engineered proteins with desired specificity: DARPins, other alternative scaffolds and bispecific IgGs. Curr Opin Struct Biol 2014; 27C:102-12; PMID:25033247; http://dx.doi.org/10.1016/j.sbi.2014.05.011
   PubMed Web of Science ®Google Scholar
• Byrne H, Conroy PJ, Whisstock JC, O'Kennedy RJ. A tale of two specificities: bispecific antibodies for therapeutic and diagnostic applications. Trends Biotechnol 2013; 31:621-32; PMID:24094861; http://dx.doi.org/10.1016/j.tibtech.2013.08.007
   PubMed Web of Science ®Google Scholar
• Anderl J, Faulstich H, Hechler T, Kulke M. Antibody-drug conjugate payloads. Methods Mol Biol 2013; 1045:51-70; PMID:23913141; http://dx.doi.org/10.1007/978-1-62703-541-5_4.
   PubMedGoogle Scholar
• Dirksen A, Madsen M, Dello Iacono G, Matin MJ, Bacica M, Stankovic N, Callans S, Bhat A. Parallel synthesis and screening of peptide conjugates. Bioconjug Chem 2014; 25:1052-60; PMID:24824568; http://dx.doi.org/10.1021/bc500129w
   PubMed Web of Science ®Google Scholar
• Yang J, Chen H, Vlahov IR, Cheng JX, Low PS. Evaluation of disulfide reduction during receptor-mediated endocytosis by using FRET imaging. Proc Natl Acad Sci U S A 2006; 103:13872-7; PMID:16950881; http://dx.doi.org/10.1073/pnas.0601455103
   PubMed Web of Science ®Google Scholar
• Zhao H, Graf O, Milovic N, Luan X, Bluemel M, Smolny M, Forrer K. Formulation development of antibodies using robotic system and high-throughput laboratory (HTL). J Pharm Sci 2010; 99:2279-94; PMID:20014026; http://dx.doi.org/10.1002/jps.22008
   PubMed Web of Science ®Google Scholar
• Samra HS, He F. Advancements in high throughput biophysical technologies: applications for characterization and screening during early formulation development of monoclonal antibodies. Mol Pharm 2012; 9:696-707; PMID:22263524; http://dx.doi.org/10.1021/mp200404c
   PubMed Web of Science ®Google Scholar
• Liu C, Tadayoni BM, Bourret LA, Mattocks KM, Derr SM, Widdison WC, Kedersha NL, Ariniello PD, Goldmacher VS, et al. Eradication of large colon tumor xenografts by targeted delivery of maytansinoids. Proc Natl Acad Sci U S A 1996; 93:8618-23; PMID:8710920;.
   PubMed Web of Science ®Google Scholar
• Whiteman KR, Johnson HA, Mayo MF, Audette CA, Carrigan CN, LaBelle A, Zukerberg L, Lambert JM, Lutz RJ. Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models. MAbs 2014; 6:556-66; PMID:24492307; http://dx.doi.org/10.4161/mabs.27756
   PubMed Web of Science ®Google Scholar
• Fleming MS, Zhang W, Lambert JM, Amphlett G. A reversed-phase high-performance liquid chromatography method for analysis of monoclonal antibody-maytansinoid immunoconjugates. Anal Biochem 2005; 340:272-8; PMID:15840500; http://dx.doi.org/10.1016/j.ab.2005.02.010
   PubMed Web of Science ®Google Scholar